Daily Brief Health Care: Bio FD&C, Anupam Rasayan, Emergency Assistance Japan C, Imugene Ltd, Laurus Labs, Abingdon Health, Shionogi & Co, CSPC Innovation Pharmaceutical-A and more

• KMF is getting ready to complete its IPO on the KOSDAQ market in November. The indicative IPO price range is 15,000 to 17,800 won per share.
• Since its establishment in 2002, KMF has developed and produced functional food and bio-materials based on fermentation and enzyme technologies.
• Total revenue and net income increased by 259% and 1,018%, respectively from 2023 to 2025. KMF’s operating margins are extremely high at 55.8% in 2025 and 51.9% in 1H 2026. 

• Anupam has moved from a largely India-based custom-synthesis company to an integrated platform spanning fluorine inputs, specialty molecules, U.S. manufacturing and finished pharmaceutical formulations.
• The integration strategy has coincided with record FY26 revenue, a sharp recovery in operating cash flow and materially better inventory and receivable days.
• The thesis is no longer just growth through capex. It is now about extracting returns from acquired assets while ensuring minority-funded consolidation translates into attributable earnings and cash.

Key points (machine generated)

• Japan Emergency Assistance Co., Ltd. reported an 8.2% increase in sales to 1.965 billion yen for Q2 of fiscal year 2026.
• Operating profit surged by 167.8% to 105 million yen, with significant growth in ordinary and net profits as well.
• The growth was driven by strategic price revisions, new orders, and increased demand from inbound tourists, with the company on track to meet its full-year performance forecast.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging pipeline into a highly-focused vehicle concentrating on CAR-T.
• It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers.
• IMU announced on 5 October 2026 that its BTKi Combination Cohort (Cohort 3) continues to progress with four additional patients evaluated at Day 28, with one Complete Response (CR) in Mantle Cell Lymphoma (MCL) and one Partial Response (PR) in Chronic Lymphocytic Leukemia (CLL).

• FY26 CDMO revenue rose 36%, while Q1 FY27 CDMO accelerated 67% and reached 43% of quarterly revenue.
• Commercial and late-stage programmes, peptides and fermentation are shifting Laurus toward higher-complexity, higher-margin outsourced development and manufacturing.
• The earnings recovery is now visible, but the valuation increasingly requires successful commissioning, utilisation and return-on-capital delivery from growth CAPEX.

• The minerals exploration and development Company announces that its joint venture partner in the Elizabeth Hill Silver Project, West Coast Silver Limited (ASX: WCE), has today announced its H2 2026 diamond drilling program at the high-grade Elizabeth Hill Silver Project in Western Australia is scheduled to commence in early to midOctober.
• The 18 diamond hole drill program for ~1,800m is commencing across the Elizabeth Hill Silver Project, aiming to advance mineral resource definition, extension and new highgrade zone definition commenced in H1 2026.
• West Core Drilling is scheduled to mobilise in the week of 5 October, with drilling expected to continue through early to mid-December. 

• Shionogi & Co (4507 JP) is acquiring the U.S.-based IntraBio for an upfront consideration of $2B. The acquisition would add FDA-approved rare disease drug Aqneursa to Shionogi’s growing portfolio.
• As Shionogi is expanding rare disease presence globally, addition of Aqneursa after its acquisition of Radicava will deepen the company’s capability in rare diseases.
• Expanding capabilities in rare disease front will facilitate to commercialize Shionogi’s rare disease pipeline, including zatolmilast (target launch in FY28) and S-606001 (expected launch in FY32).

• Structural Overcapacity in Caffeine Squeezes Margins: The global synthetic caffeine market—where CSPC Innovation holds a 60% to 70% global demand share—is suffering from persistent overcapacity. Increased capacity inside China drove a margin compression from 47% to 34%, leading to consecutive net losses of RMB 304 million in 2024 and RMB 634 million in 2025.
• Biopharma Pivot Masked by Volatile BD Revenues: While the company swung to a net profit of RMB 1.18 billion to RMB 1.36 billion in H1 2026, this turnaround is entirely driven by lumpy out-licensing (BD) payments—primarily the US$1.2 billion upfront from the AstraZeneca weight management deal. Commercial product revenues from proprietary drugs remain minimal, meaning near-term earnings will remain highly volatile.
• H-Share Listing and Capital Strategy: The planned US$500 million H-share listing in Hong Kong is intended to establish an offshore financing platform to shield the company’s capital-intensive ADC and mRNA pipelines from domestic A-share liquidity constraints. This capital is key to funding Phase III trials for their EGFR ADC SYS6010 and capital expenditures for their new 51%-49% manufacturing joint venture with AstraZeneca in Shijiazhuang.